NCT05799131尚未招募不适用
QBX (5F/6F) Peripheral Balloon Expandable Stent System for the Treatment of Peripheral Artery Disease (PAD): Assessing Safety and Clinical Performance up to 12-months Follow-up
QualiMed Innovative Medizinprodukte GmbH4 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- To evaluate the cumulative rate of MAVE.
研究概览
简要总结
This study aims to evaluate the safety and performance of the QBX stent system in the treatment of PAD by reporting of peri- and postoperative complications, including major adverse vascular events (MAVE), Vascular Access Site Complications (VASCs) and bleeding at puncture site, and by evaluating the prevalence of Target Vessel Revascularization (TVR), amputations, procedural success, device performance, reduction in percentage diameter stenosis post-procedure compared to pre-procedure, artery patency, return to normal activity, Rutherford and Fontaine classification, quality of life (QoL), Ankle Brachial Index (ABI), and hospital- and patient-related costs in a prospectively maintained database.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient eligible for implantation of a peripheral balloon-expandable stent.
- •Target lesion is an occlusion or diameter stenosis is ≥50% by visual estimate.
- •Target lesion is a de novo or restenotic lesion.
- •Target lesion is located in the external iliac artery (EIA), internal iliac artery (IIA), common iliac artery (CIA), superficial femoral artery (SFA) and/or deep femoral artery (DFA). Bilateral treatment of the target lesions is allowed. There are no restrictions on the number of target lesions treated with QBX or the number of stents used. Kissing stents and overlapping stents are allowed to treat the target lesions.
- •Patient suffers from mild to intermittent claudication (Rutherford 1-3) or critical limb ischemia (Rutherford 4-5).
- •Patients with TASC A, B, C and D lesions.
- •Patient ≥ 18 years of age at study entry.
- •Patient and investigator signed and dated the informed consent form prior to the index-procedure.
排除标准
- •Age < 18 y.
- •Pregnant women, women who are currently breastfeeding, women of childbearing potential who are not using an effective method of contraception, or women planning to become pregnant during the course of the study.
- •Patients with Rutherford 0 and
- •Patient received a different stent device than the study device for the target lesion.
- •Target lesion cannot be crossed with a guidewire (e.g. heavily calcified or excessively tortuous target lesion).
- •Reference vessel diameter is not suitable for the available stent design.
- •Target lesion was previously treated with a stent.
- •Target lesion is in a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis.
- •Presence of significant stenosis (≥50%) or occlusion of inflow tract not successfully treated before or during the index-procedure (success is measured as < 30% residual stenosis and absence of distal embolization).
- •Outflow: In case of treatment of iliac arteries: Inadequate distal runoff with > 50% stenosis of either the common femoral artery or both the superficial and deep femoral arteries. In case of treatment of the SFA: Absence of at least one patent runoff vessel with ≤ 50% stenosis throughout its course (i.e., confirmed in-line patency to the level of the foot). Outflow can be treated before or during the index-procedure (success is measured as < 30% residual stenosis and absence of distal embolization).
- •Presence of active inflammation at the planned access site.
- •Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index-procedure.
- •Patients in severe renal failure (estimated Glomerular filtration rate (eGFR) < 25 mL/min/1.73m). Lab results are maximum 30 days old.
- •Patient has a persistent acute intraluminal thrombus of the target lesion.
- •Target lesion is in an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion.
- •Patient has an abdominal aortic aneurysm contiguous with an iliac artery target lesion.
- •Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability.
- •Contraindication for anti-coagulation therapy (coagulopathy, etc.).
- •Patient has a known intolerance to contrast agents. If hypersensitivity to contrast agents in patients with prior reactions could be improved by premedication and changing the contrast agent, the patient can be included in the study.
- •Patients has a known hypersensitivity to the stent material (L605).
- •Patient has a life expectancy of <12 months.
- •Patient has a planned surgical intervention/procedure, interfering with the study (results), within 30 days of the study procedure.
- •Patient is considered to be hemodynamically unstable at onset of index-procedure.
- •Patient is currently participating in a confounding study.
- •Patient is unable to comply with the protocol or proposed follow-up visits.
- •Patient is unable / unwilling to provide informed consent.
结局指标
主要结局
To evaluate the cumulative rate of MAVE.
时间窗: 12-months follow-up
MAVE is defined as: 1. Device- or procedure-related death; 2. Target Lesion Revascularization (TLR) at 12 months, defined as a repeated procedure (endovascular or open surgery) due to a problem arising from the lesion (+1 cm proximally and distally to include edge phenomena) initially treated; 3. Device-related distal embolization that required hospitalization and/or subsequent intervention.
次要结局
- Intra-operative complication rate.(Index-procedure)
- Amputation rate(12-months follow-up)
- Procedural success.(Index-procedure)
- Post-operative complication rate.(12-months follow-up)
- Re-occlusion rate.(12-months follow-up)
- Secondary sustained clinical improvement at 12 months.(12-months follow-up)
- Ankle Brachial Index (ABI) during follow-up as compared to baseline.(12-months follow-up)
- Rate of subjects with Vascular Access Site Complications (VASCs) within the first 24h after the index-procedure(24 hours)
- Intra-operative absence of bleeding at puncture site.(Index-procedure)
- Target Vessel Revascularization (TVR) rate.(12-months follow-up)
- Technical success(Index-procedure)
- Reduction in percentage diameter stenosis post-procedure compared to pre-procedure.(Index-procedure)
- Device success.(Index-procedure)
- Distribution of Fontaine stages during follow-up as compared to baseline.(12-months follow-up)
- Improvement in disease-related health status, functioning and quality of life at follow-up as compared to baseline.(12-months follow-up)
- Return to normal activity.(1-month follow-up)
- Device performance.(Index-procedure)
- Occurrence of prolonged hospitalization compared to local standard of care (SOC).(Immediately after the procedure)
- Time taken off from work for the procedure(1-month follow-up)
- Artery patency.(12-months follow-up)
- Distribution of Rutherford classes during follow-up as compared to baseline.(12-months follow-up)
- Primary sustained clinical improvement at 12 months.(12-months follow-up)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Efficacy and safety of CP stent implantation for pulmonary stenosis associated with congenital heart diseasesPulmonary stenosis associated with congenital heart diseasesJPRN-jRCT1092220172Hideshi Tomita25
已完成
3 期
Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)Coronary Artery DiseaseNCT00231244Cordis Corporation252
已完成
4 期
The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher StentCoronary Artery DiseaseNCT00232804Cordis Corporation639
已完成
3 期
Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac ArteryPeripheral Vascular DiseaseNCT01396525Abbott Medical Devices153
已完成
不适用
A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery SystemIliac Artery Occlusive DiseaseNCT00561457C. R. Bard134